Structures by: Ueto T.
Total: 9
C21.5H18F3N5O3.5S2
C21.5H18F3N5O3.5S2
CrystEngComm (2018) 20, 3 362
a=11.2642(2)Å b=20.5587(4)Å c=10.11845(18)Å
α=90.0000° β=91.9094(7)° γ=90.0000°
C21.5H17F3N5O4S2
C21.5H17F3N5O4S2
CrystEngComm (2018) 20, 3 362
a=11.4209(2)Å b=20.5581(4)Å c=9.97928(18)Å
α=90.0000° β=91.5970(11)° γ=90.0000°
C21H16.5Cl0.5F3N5O3S2
C21H16.5Cl0.5F3N5O3S2
CrystEngComm (2018) 20, 3 362
a=11.24851(18)Å b=20.6292(4)Å c=10.0577(2)Å
α=90.0000° β=91.7969(9)° γ=90.0000°
C21.5H18F3N5O3.5S2
C21.5H18F3N5O3.5S2
CrystEngComm (2018) 20, 3 362
a=11.2994(2)Å b=20.5599(4)Å c=10.11464(18)Å
α=90.0000° β=92.3835(8)° γ=90.0000°
Furosemide nicotinamide 1:1 cocrystal form I
C12H11ClN2O5S,C6H6N2O
Crystal Growth & Design (2012) 12, 1 485
a=4.86286(13)Å b=20.7109(6)Å c=19.3632(5)Å
α=90° β=92.4168(6)° γ=90°
Furosemide nicotinamide 1:1 cocrystal form II
C12H11ClN2O5S,C6H6N2O
Crystal Growth & Design (2012) 12, 1 485
a=16.4686(4)Å b=5.01253(14)Å c=24.7963(7)Å
α=90° β=108.8400(6)° γ=90°
Furosemide nicotinamide 1:1 cocrystal form III
C12H11ClN2O5S,C6H6N2O
Crystal Growth & Design (2012) 12, 1 485
a=5.22828(4)Å b=18.71272(17)Å c=20.12138(18)Å
α=90° β=94.8246(5)° γ=90°
Furosemide nicotinamide 1:1 cocrystal form IV
C12H11ClN2O5S,C6H6N2O
Crystal Growth & Design (2012) 12, 1 485
a=40.6357(13)Å b=5.36051(15)Å c=18.3727(5)Å
α=90° β=92.5034(13)° γ=90°
Furosemide nicotinamide 1:1 cocrystal hydrate
C12H11ClN2O5S,C6H6N2O,2(H2O)
Crystal Growth & Design (2012) 12, 1 485
a=46.9784(16)Å b=5.09800(15)Å c=18.1866(6)Å
α=90.0000° β=92.5680(18)° γ=90.0000°